BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream' - 2Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 3US FDA unveils new pathway to approve personalized therapies
- 4Explainer-What will change with the US reclassification of marijuana?
- 5Help Your Efficiency with These Work area Updates
- Vote In favor of Your Favored Pizza Cover
- Vote in favor of Your #1 4\u00d74 SUVs
- 15 Outrageous Cosplay Outfits That Will Blow You Away
- Starfront Observatories: A haven for distant stargazers
- A NASA spacecraft orbiting Mars may be dead
- Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- Foot fossil discovery could reshape human evolutionary history
- A Manual for SUVs with Less Noteworthy Gas Mileage
- Why doing good also makes us feel good, during the holidays and beyond
